In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.
Traci DeVito
Advertisement
Articles by Traci DeVito
Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.
Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.
The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.
Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.
Advertisement
Latest Updated Articles
Biosimilars: New Avenues for the Practicing Oncologist Treating Breast CancerPublished: October 25th 2018 | Updated:
The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell LymphomaPublished: December 6th 2018 | Updated:
Key Advances in Oncology, 2018Published: January 17th 2019 | Updated:
Oncology Conference Highlights, Q4Published: January 17th 2019 | Updated:
FDA Approves Two New Indications and Dosage Form for PembrolizumabPublished: May 14th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Revumenib in R/R NPM1-Mutant AML
2
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
3
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
